Replies to post #24 on Akero Therapeutics Inc (AKRO)

[stocksrising]

Starter position down here, mid $15’s…don’t follow company, but sell side folks seem
To give them more time to develop
Readouts in q1/2024…also:


Akero's cash, cash equivalents and short-term and long-term marketable securities for the period ended June 30, 2023 were $658.9 million.
Akero believes that its current cash, cash equivalents, short-term and long-term marketable securities will be sufficient to fund its current operating plan into 2026.